Raras
Buscar doenças, sintomas, genes...
Ataxia espinocerebelar tipo 49
ORPHA:631106CID-10 · G11.4CID-11 · 8A03.16OMIM 619806DOENÇA RARA

Doença de Machado-Joseph (DMJ), também conhecida por ataxia SCA3, é uma neuropatologia rara, de origem genética, que se manifesta por uma progressiva ataxia cerebelar traduzida em crescente perda do controle muscular e da coordenação motora nos membros superiores e inferiores, oftalmoplegia, perturbações da visão e dificuldades na fala e no engolir.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Ataxia espinocerebelar tipo 49 (SCA49) é uma doença neurodegenerativa autossômica dominante causada por mutações no gene SAMD9L. Manifesta-se com ataxia progressiva, perda da marcha, disartria, dismetria, estrabismo e sinais piramidais como Babinski e hiperreflexia.

Publicações científicas
8.166 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
9
pacientes catalogados
Início
Adolescent
+ adult, childhood
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G11.4
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
5 sintomas
👁️
Olhos
2 sintomas

+ 13 sintomas em outras categorias

Características mais comuns

100%prev.
Hiperreflexia
Frequência: 9/9
100%prev.
Atrofia cerebelar
Frequência: 5/5
100%prev.
Nistagmo evocado pelo olhar
Frequência: 9/9
78%prev.
Ataxia
Frequência: 7/9
78%prev.
Dismetria
Frequência: 7/9
67%prev.
HP:0003596
Frequência: 6/9
20sintomas
Muito frequente (3)
Frequente (6)
Ocasional (7)
Muito raro (2)
Sem dados (2)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 20 características clínicas mais associadas, ordenadas por frequência.

HiperreflexiaHyperreflexia
Frequência: 9/9100%
Atrofia cerebelarCerebellar atrophy
Frequência: 5/5100%
Nistagmo evocado pelo olharGaze-evoked nystagmus
Frequência: 9/9100%
Ataxia
Frequência: 7/978%
DismetriaDysmetria
Frequência: 7/978%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Total histórico8.166PubMed
Últimos 10 anos63publicações
Pico202313 papers
Linha do tempo
20202015Hoje · 2026📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

SAMD9LSterile alpha motif domain-containing protein 9-likeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in endosome fusion. Mediates down-regulation of growth factor signaling via internalization of growth factor receptors

LOCALIZAÇÃO

Early endosomeMitochondrion

MECANISMO DE DOENÇA

Ataxia-pancytopenia syndrome

An autosomal dominant disorder characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to bone marrow failure and myeloid leukemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
55.2 TPM
Baço
34.1 TPM
Pulmão
22.9 TPM
Nervo tibial
17.2 TPM
Cervix Endocervix
14.3 TPM
OUTRAS DOENÇAS (4)
monosomy 7 myelodysplasia and leukemia syndrome 1ataxia-pancytopenia syndromespinocerebellar ataxia 49SAMD9L-associated autoinflammatory syndrome
HGNC:1349UniProt:Q8IVG5

Variantes genéticas (ClinVar)

365 variantes patogênicas registradas no ClinVar.

🧬 SAMD9L: NM_152703.5(SAMD9L):c.4417A>G (p.Ser1473Gly) ()
🧬 SAMD9L: NM_152703.5(SAMD9L):c.3329A>C (p.Lys1110Thr) ()
🧬 SAMD9L: NM_152703.5(SAMD9L):c.347C>T (p.Ser116Leu) ()
🧬 SAMD9L: NM_152703.5(SAMD9L):c.-1043+2T>C ()
🧬 SAMD9L: NM_152703.5(SAMD9L):c.2500G>T (p.Val834Leu) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 5,215 variantes classificadas pelo ClinVar.

1043
1043
3129
Patogênica (20.0%)
VUS (20.0%)
Benigna (60.0%)
VARIANTES MAIS SIGNIFICATIVAS
FGF14: NM_004115.4(FGF14):c.353G>T (p.Gly118Val) [Pathogenic]
GRM1: NM_001278064.1(GRM1):c.[2652_2654delGAA;2660+2T>G] [Pathogenic]
PUM1: NM_001020658.2(PUM1):c.1544dup (p.Asn516fs) [Likely pathogenic]
PUM1: GRCh38/hg38 1p35.2(chr1:30936422-30948423)x3 [Pathogenic]
TDP1: NM_018319.4(TDP1):c.1317G>A (p.Leu439=) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Ataxia espinocerebelar tipo 49

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
3.160 papers (10 anos)

Mostrando amostra de 63 publicações de um total de 3.160

#1

Precision Diagnosis of Wilson Disease Using a MultiGene Panel: Insights From a Prospective Cohort Study.

Neurology. Genetics2026 Apr

Wilson disease (WD) is an autosomal recessive disorder of copper metabolism. Conventional genetic diagnostics are low-throughput and may miss intronic, structural, or phenocopy variants, leading to delayed or missed diagnoses. In this study, we evaluate the utility of a custom next-generation sequencing (NGS) panel targeting the full-length ATP7B gene and 10 additional copper metabolism-related genes in patients with clinically suspected WD. We conducted a prospective cohort study of 144 individuals at our neurogenetic center. Variants identified by NGS were filtered and annotated with in silico tools and classified according to American College of Medical Genetics and Genomics guidelines. Confirmatory Sanger sequencing, multiplex ligation-dependent probe amplification, and reverse transcription PCR assays were performed as needed. Genetic confirmation of WD was achieved in 129 of 144 patients (90%), including 80 typical (Leipzig score ≥4) and 49 atypical (score <4) cases. Ten novel ATP7B variants, including deep intronic, noncanonical splice, and copy number variants, were identified using this panel. Among 15 genetically unresolved cases, 6 harbored variants in other copper metabolism-related genes but no pathogenic ATP7B variants. Notably, 1 patient with a Leipzig score of 4 had been clinically diagnosed with WD for years but was reclassified as spinocerebellar ataxia type 12 after panel testing revealed only a heterozygous CP variant and a CAG repeat expansion in PPP2R2B. Our comprehensive multigene NGS panel enables precise diagnosis of WD by detecting both classical and unconventional pathogenic variants, as well as distinguishing phenocopies. This improved diagnostic accuracy underscores the value of early genetic testing to guide timely intervention, especially in atypical or early-stage cases.

#2

Spinocerebellar Ataxia Type 6 Initially Diagnosed as Alcoholic Cerebellar Degeneration: A Case Report.

Internal medicine (Tokyo, Japan)2026 Feb 10

Spinocerebellar ataxia type 6 (SCA6) is an autosomal dominant adult-onset neurodegenerative disorder. Cases may appear sporadic when the family history is uninformative or relatives' symptoms are unrecognized as disease-related. We herein report a 49-year-old male with no family history of ataxia but with excessive alcohol consumption, initially diagnosed with alcoholic cerebellar degeneration (ACD) and subsequently identified as having SCA6. Diagnosing ACD is difficult because reliable diagnostic markers and threshold levels of alcohol intake predicting cerebellar degeneration are lacking. Alternative diagnoses, including SCA6, should be considered when clinical or imaging findings are atypical and the family history is uninformative.

#3

Novel ATXN10 Repeat Motif Patterns in Peruvian Families Modify Disease Onset.

Neurology. Genetics2025 Dec

Spinocerebellar ataxia type 10 (SCA10) is an autosomal-dominant disorder caused by intronic expansions of pentanucleotide repeats in the ATXN10 gene. While various repeat motifs have been described, emerging evidence suggests that specific repeat motifs, rather than repeat length alone, can modify disease features such as seizure prevalence and penetrance. We used a novel multiplex 20-gene panel with Cas9-targeted, amplification-free long-read sequencing (LRS) and optical genome mapping to elucidate ATXN10 repeat motif patterns and investigated genotype-phenotype correlations in index cases of 6 multigenerational SCA10 kindreds from Peru. We detected ATXN10 repeat expansions ranging from 990 to 2,002 pentanucleotide repeats (4.9-10 kb) across 6 families. It is important to note that we identified 3 mixed repeat motif patterns and ratios of (ATTCT)n(ATTCC)n, which were associated with differences in age at disease onset and anticipation. Our key novel finding is the prominence of the alternate ATTCC motif alongside the common ATTCT motif. While repeat length alone does not appear to drive disease onset in SCA10, we uncovered that the ratio of the ATTCC motif within distinct repeat patterns might correlate with disease onset. These findings underscore the need to adapt LRS clinical workflows to fully characterize large repeat expansions at the nucleotide level.

#4

Altered static and dynamic spontaneous brain activity patterns in spinocerebellar ataxia type3 patients.

Journal of neurology2025 Aug 04

Spinocerebellar ataxia type 3 (SCA3) is characterized by extensive supra- and infra-tentorial brain injuries, beginning in the pre-symptomatic stage. However, the alterations and evolution of spontaneous brain activity in SCA3 patients remain poorly understood. This study aimed to investigate the abnormal brain activity of SCA3, classified it into distinct patterns, and explored the association between spontaneous brain activity in affected regions and clinical variables. Ninety-nine SCA3 patients (76 sym- and 23 pre-SCA3 patients, mean age: 39.97 ± 10.83y; 28.74 ± 7.99y) and 49 healthy controls underwent 3.0T MRI and acquired T1 and resting-state functional MRI images. The static and dynamic amplitude of low-frequency fluctuation (s/dALFF) and regional homogeneity (s/dReHo) were used to estimate local brain activity alterations. SCA3 patients exhibited significantly abnormal spontaneous brain activities in multiple regions, classified into four patterns (P < 0.001). Patterns 1 and 2 were found in the pre-symptomatic stage, involving the right opercular part of inferior frontal gyrus, right rolandic operculum, right insula, right angular gyrus, right crus I of cerebellar hemisphere and left superior frontal gyrus. Pattern 3 emerged in symptomatic SCA3, with expanded involvement of supra- to infra-tentorial regions. Pattern 4 showed increased activity in the right cerebellar lobule IX. Negative correlations were found between sReHo value in the right anterior cingulate cortex with the disease duration and severity (P ≤ 0.04). SCA3 patients exhibit different patterns of brain activity damage at different stages. These findings provide new insight into brain dysfunction in SCA3 and suggest potential imaging markers for disease staging and monitoring.

#5

Quantification of liver fat fraction using T1-weighted mDixon MRI in young patients with ataxia telangiectasia undergoing whole-body MRI: an exploratory study.

Orphanet journal of rare diseases2025 Jun 21

Ataxia-telangiectasia (A-T) is an inherited multiorgan disorder with onset in childhood. Liver involvement, with steatosis and subsequent fibrosis, is increasingly recognized in children and young people with A-T. To evaluate feasibility of T1-weighted two-point mDixon MRI for identification of liver steatosis in children with A-T and conduct exploratory analysis of relationships between MRI-quantified liver fat fraction and clinical and laboratory measures. Post hoc analysis of prospectively collected research data. 16 participants (8 female) with A-T aged 4.8-16.6 years. 3.0-T, two-point T1-weighted mDixon. Participants underwent whole-body MRI including T1-weighted mDixon. Water/fat signal percentage images were generated. Hepatic T1 fat fraction (T1-FF) was calculated from regions-of-interest placed in the right anterior, right posterior and left hepatic lobes. T1-FF > 5.56% was used as the diagnostic criterion for hepatic steatosis. Group comparisons of variables between participants with and without previous diagnosis of liver steatosis were made using independent sample Mann-Whitney U. Associations between T1-FF and age, neurological severity and of liver function tests were tested with Spearman correlation. Statistical significance was pre-specified as p < 0.05. Analyzable T1-weighted mDixon data was available for 11 participants. Five MRI datasets were discarded due to motion artefact (n = 3) or incorrect archiving of the original water image (n = 2). Median liver T1-FF was 11.3% (4.7-49.7%), and 10/11 (91%) of participants had evidence of steatosis. Participants with previous diagnosis of steatosis had higher T1-FF than those without (median 32.7% [9.7-49.7%], versus 10.3% [4.7-11.3%], p = 0.030). T1-FF correlated most strongly with alanine transaminase (r = 0.76, p = 0.007) and γ-glutamyltransferase (r = 0.76, p = 0.006). T1-weighted mDixon MRI is feasible for detecting steatosis in children with A-T, although motion artefacts reduced data completeness. MRI-quantified liver T1-FF correlates with markers of liver health. We found higher prevalence of liver steatosis using T1-weighted mDIXON than previously reported in pediatric A-T cohorts.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC3.032 artigos no totalmostrando 63

2026

Precision Diagnosis of Wilson Disease Using a MultiGene Panel: Insights From a Prospective Cohort Study.

Neurology. Genetics
2026

Spinocerebellar Ataxia Type 6 Initially Diagnosed as Alcoholic Cerebellar Degeneration: A Case Report.

Internal medicine (Tokyo, Japan)
2025

Pragmatic Feasibility Study Combining Cerebello-spinal Neuromodulation and Exercise in Spinocerebellar Ataxia Type 3: A 20-session Single-arm Protocol.

Cerebellum (London, England)
2025

Novel ATXN10 Repeat Motif Patterns in Peruvian Families Modify Disease Onset.

Neurology. Genetics
2025

Nerve Fiber Bundle Damage in Spinocerebellar Degeneration on Diffusion Tensor Imaging.

Current medical imaging
2025

Spastic Ataxia Composite (SPAXCOM): A Scale to Evaluate the Progression of Subjects with Spasticity and Ataxia.

Movement disorders : official journal of the Movement Disorder Society
2025

Familial spinocerebellar ataxia type 3: A case report of multi-generational presentation.

Medicine
2025

Altered static and dynamic spontaneous brain activity patterns in spinocerebellar ataxia type3 patients.

Journal of neurology
2025

Quantification of liver fat fraction using T1-weighted mDixon MRI in young patients with ataxia telangiectasia undergoing whole-body MRI: an exploratory study.

Orphanet journal of rare diseases
2025

Diplopia in the Spinocerebellar Ataxias: Prevalence, Risk Factors, and Association with Falls.

Neuro-ophthalmology (Aeolus Press)
2025

TBP Repeat Expansion Analysis in Patients Carrying Heterozygous STUB1 Variants.

Movement disorders : official journal of the Movement Disorder Society
2025

Movement Disorders in Hereditary Cerebellar Ataxia.

Movement disorders clinical practice
2024

Cerebellar type 1 metabotropic glutamate receptor availability decreases with disease progression in spinocerebellar ataxia type 6.

Journal of the neurological sciences
2025

Spinocerebellar ataxia type 49 presenting with ataxia, early onset dystonia, and bradykinesia in an Indian female patient.

Parkinsonism &amp; related disorders
2024

Polyneuropathy in Patients with Spinocerebellar Ataxias Types 2, 3, and 10: A Systematic Review.

Cerebellum (London, England)
2024

Imbalanced optimal feedback motor control system in spinocerebellar ataxia type 3.

European journal of neurology
2024

GAA-FGF14 disease: defining its frequency, molecular basis, and 4-aminopyridine response in a large downbeat nystagmus cohort.

EBioMedicine
2023

UNC-49 is a redox-sensitive GABAA receptor that regulates the mitochondrial unfolded protein response cell nonautonomously.

Science advances
2023

An autopsy case of late-onset spinocerebellar atrophy type 14.

Neuropathology and applied neurobiology
2023

A child with polyarthritis and chronic lung disease: a case report of ataxia-telangiectasia.

Italian journal of pediatrics
2023

Inactivating TDP2 missense mutation in siblings with congenital abnormalities reminiscent of fanconi anemia.

Human genetics
2023

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.

International journal of molecular sciences
2023

Design, synthesis and biological evaluation of pyrrolopyrimidine derivatives as novel and selective positive modulator of the small conductance Ca2+-activated K+ channels.

European journal of medicinal chemistry
2023

Motor neuron involvement threatens survival in spinocerebellar ataxia type 1.

Neuropathology and applied neurobiology
2023

Gene therapy for selected neuromuscular and trinucleotide repeat disorders - An insight to subsume South Asia for multicenter clinical trials.

IBRO neuroscience reports
2023

A standardised protocol for blood and cerebrospinal fluid collection and processing for biomarker research in ataxia.

Neuropathology and applied neurobiology
2022

Spinocerebellar ataxia type 17-digenic TBP/STUB1 disease: neuropathologic features of an autopsied patient.

Acta neuropathologica communications
2023

Intermediate repeat expansions of TBP and STUB1: Genetic modifier or pure digenic inheritance in spinocerebellar ataxias?

Genetics in medicine : official journal of the American College of Medical Genetics
2023

Cerebello-cerebral resting-state functional connectivity in spinocerebellar ataxia type 3.

Human brain mapping
2023

Primary degeneration of oculomotor, motor, and somatosensory systems and auditory and visual pathways in spinocerebellar ataxia type 7: A clinicopathological study in a Japanese autopsy case.

Neuropathology : official journal of the Japanese Society of Neuropathology
2022

The Natural History of Spinocerebellar Ataxia Type 3 in Mainland China: A 2-Year Cohort Study.

Frontiers in aging neuroscience
2022

Magnetic Resonance Imaging and Its Clinical Correlation in Spinocerebellar Ataxia Type 3: A Systematic Review.

Frontiers in neuroscience
2022

Rovatirelin ameliorates motor dysfunction in the cytosine arabinoside-induced rat model of spinocerebellar degeneration via acetylcholine and dopamine neurotransmission.

Clinical and experimental pharmacology &amp; physiology
2022

Clinical, Radiological, and Genetic Profile of Spinocerebellar Ataxia 12: A Hospital-Based Cohort Analysis.

Tremor and other hyperkinetic movements (New York, N.Y.)
2022

Hypothalamic Atrophy, Expanded CAG Repeat, and Low Body Mass Index in Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society
2022

Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial.

The Lancet. Neurology
2022

Digenic inheritance of STUB1 variants and TBP polyglutamine expansions explains the incomplete penetrance of SCA17 and SCA48.

Genetics in medicine : official journal of the American College of Medical Genetics
2021

Homozygous spinocerebellar ataxia type 3 in China: a case report.

The Journal of international medical research
2021

Mechanisms of repeat-associated non-AUG translation in neurological microsatellite expansion disorders.

Biochemical Society transactions
2021

Evidence for Non-Mendelian Inheritance in Spastic Paraplegia 7.

Movement disorders : official journal of the Movement Disorder Society
2023

Wheelchair mobility, motor performance and participation of adult wheelchair users with ARSACS: a cross-sectional study.

Disability and rehabilitation. Assistive technology
2020

Spinocerebellar Ataxia Type 6: A Disorder of Connectivity?

The Journal of neuroscience : the official journal of the Society for Neuroscience
2021

Static and Dynamic Ocular Motor Abnormalities as Potential Biomarkers in Spinocerebellar Ataxia Type 3.

Cerebellum (London, England)
2020

Gray matter atrophy patterns within the cerebellum-neostriatum-cortical network in SCA3.

Neurology
2020

Clinical features and genetic characteristics of homozygous spinocerebellar ataxia type 3.

Molecular genetics &amp; genomic medicine
2020

Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1.

Movement disorders clinical practice
2019

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.

Molecular neurodegeneration
2019

Macular degeneration as a common cause of visual loss in spinocerebellar ataxia type 1 (SCA1) patients.

Ophthalmic genetics
2018

Intronic pentanucleotide TTTCA repeat insertion in the SAMD12 gene causes familial cortical myoclonic tremor with epilepsy type 1.

Brain : a journal of neurology
2018

Assessing mobility and balance in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay population: Validity and reliability of four outcome measures.

Journal of the neurological sciences
2020

Body composition in Spinocerebellar ataxia type 3 and 10 patients: Comparative study with control group.

Nutritional neuroscience
2018

Very High Frequency Oscillations of Heart Rate Variability in Healthy Humans and in Patients with Cardiovascular Autonomic Neuropathy.

Advances in experimental medicine and biology
2019

Why do so many genetic insults lead to Purkinje Cell degeneration and spinocerebellar ataxia?

Neuroscience letters
2018

The progression rate of spinocerebellar ataxia type 2 changes with stage of disease.

Orphanet journal of rare diseases
2018

Peripheral markers of autophagy in polyglutamine diseases.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2017

Haplotype Study in SCA10 Families Provides Further Evidence for a Common Ancestral Origin of the Mutation.

Neuromolecular medicine
2017

Spinocerebellar ataxia type 29 due to mutations in ITPR1: a case series and review of this emerging congenital ataxia.

Orphanet journal of rare diseases
2017

NESSCA Validation and Responsiveness of Several Rating Scales in Spinocerebellar Ataxia Type 2.

Cerebellum (London, England)
2016

Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
2016

Liver Disease in Pediatric Patients With Ataxia Telangiectasia: A Novel Report.

Journal of pediatric gastroenterology and nutrition
2016

Development of global rating instruments for pediatric patients with ataxia telangiectasia.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2015

Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study.

The Lancet. Neurology
2015

Population genetics and new insight into range of CAG repeats of spinocerebellar ataxia type 3 in the Han Chinese population.

PloS one
Ver todos os 3.032 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Ataxia espinocerebelar tipo 49.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Ataxia espinocerebelar tipo 49

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Precision Diagnosis of Wilson Disease Using a MultiGene Panel: Insights From a Prospective Cohort Study.
    Neurology. Genetics· 2026· PMID 41788301mais citado
  2. Spinocerebellar Ataxia Type 6 Initially Diagnosed as Alcoholic Cerebellar Degeneration: A Case Report.
    Internal medicine (Tokyo, Japan)· 2026· PMID 41672535mais citado
  3. Novel ATXN10 Repeat Motif Patterns in Peruvian Families Modify Disease Onset.
    Neurology. Genetics· 2025· PMID 41229449mais citado
  4. Altered static and dynamic spontaneous brain activity patterns in spinocerebellar ataxia type3 patients.
    Journal of neurology· 2025· PMID 40760188mais citado
  5. Quantification of liver fat fraction using T1-weighted mDixon MRI in young patients with ataxia telangiectasia undergoing whole-body MRI: an exploratory study.
    Orphanet journal of rare diseases· 2025· PMID 40542396mais citado
  6. Therapeutic targeting of blood-derived protein infiltration to modulate neuroinflammation in cerebellar ataxia.
    J Neuroinflammation· 2026· PMID 41992320recente
  7. Association Between Cerebellar Metabolic Markers and Activities of Daily Living in Patients With Spinocerebellar Ataxia Type 3.
    Mol Genet Genomic Med· 2026· PMID 41983302recente
  8. Long term administration of selective NMDA GluN2B receptor blocker Ro25-6981 attenuates neurodegeneration in mouse model of spinocerebellar ataxia type 1 (SCA1).
    Cell Death Discov· 2026· PMID 41974656recente
  9. Cell-Based Therapies for Spinocerebellar Degenerations: A Systematic Review of Human Clinical Evidence.
    Cerebellum· 2026· PMID 41968234recente
  10. Comprehensive Review of Anesthetic Strategies for Patients With Neurodegenerative Diseases.
    Med Sci Monit· 2026· PMID 41964193recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:631106(Orphanet)
  2. OMIM OMIM:619806(OMIM)
  3. MONDO:0030805(MONDO)
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Ataxia espinocerebelar tipo 49
Compêndio · Raras BR

Ataxia espinocerebelar tipo 49

ORPHA:631106 · MONDO:0030805
Prevalência
<1 / 1 000 000
Casos
9 casos conhecidos
Herança
Autosomal dominant
CID-10
G11.4 · Paraplegia espástica hereditária
CID-11
Início
Adolescent, Adult, Childhood
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C5816772
Repurposing
1 candidato
taltirelinthyrotropin releasing hormone receptor agonist
EuropePMC
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades